This is a case report about one 51-year-old man with metastatic pancreatic ductal adenocarcinoma, a hard-to-treat cancer. He received several treatments, including KN046, gemcitabine, nab-paclitaxel, FOLFIRINOX, and later other drugs. He lived 30 months from his initial diagnosis. About 3.5 months before the report, doctors found cancer had spread to the lining of his brain and spinal cord, called leptomeningeal metastasis. He was treated with a ventriculoperitoneal shunt, an Ommaya reservoir, and intrathecal methotrexate plus dexamethasone, along with toripalimab and bevacizumab. The report also notes a pathological complete response (ypT0N0, R0) at some point. No side effects or safety details were reported. The main reason to be careful is that this is a single case, so it cannot show that any treatment caused this outcome or that others will have the same result. The report suggests that patients with pancreatic cancer who live longer may need prompt evaluation of new neurological symptoms. Readers should talk with their doctor about their own situation.
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary RelapseLong Survival in Pancreatic Cancer Can Bring Brain Spread
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a single case report of a 51-year-old man with metastatic pancreatic ductal adenocarcinoma (PDAC) and leptomeningeal metastasis (LM). The report also includes a review of 29 other cases, but the primary data is a single case report.
The patient received KN046, gemcitabine, nab-paclitaxel, FOLFIRINOX, a ventriculoperitoneal shunt, an Ommaya reservoir, intrathecal methotrexate plus dexamethasone, toripalimab, and bevacizumab. Survival was 30 months since initial diagnosis and 3.5 months after LM diagnosis. A pathological response of ypT0N0, R0 was reported.
Adverse events, serious adverse events, discontinuations, and tolerability were not reported. The authors note the limitation inherent to a case report. Funding and conflicts of interest were not reported.
The report suggests that treatment-responsive, HRR pathway-altered PDAC may survive long enough for CNS sanctuary relapse and highlights the need for prompt evaluation of new neurological symptoms in long-surviving patients. These observations are hypothesis-generating and should not be used to guide practice without confirmation in larger studies.
How this fits prior evidence
This case report extends prior coverage of pancreatic cancer outcomes by describing a long-surviving patient with HRR pathway-altered PDAC who developed leptomeningeal metastasis. It contrasts with the comparative efficacy finding that gemcitabine plus nab-paclitaxel demonstrates superior OS and PFS compared to modified FOLFIRINOX in unresectable cases, as this patient received both regimens. The report also aligns with the note that the immune classical subtype is associated with superior PFS and OS in metastatic pancreatic cancer, though this case did not report subtype. It addresses a gap in recognizing CNS sanctuary relapse in long survivors.
Common questions
What is leptomeningeal metastasis?
Leptomeningeal metastasis is when cancer spreads to the lining of the brain and spinal cord. In this case report, a man with pancreatic cancer developed it about 3.5 months before the report. It can cause neurological symptoms. This is a serious condition, and anyone with new neurological symptoms should see their doctor promptly.
How long did the patient live?
The report says the man lived 30 months since his initial pancreatic cancer diagnosis. He lived 3.5 months after the leptomeningeal metastasis was found. This is a single case, so it does not predict how long other people will live. Survival can vary widely.
What treatments did the patient receive?
He received KN046, gemcitabine, nab-paclitaxel, FOLFIRINOX, and later a ventriculoperitoneal shunt, an Ommaya reservoir, intrathecal methotrexate plus dexamethasone, toripalimab, and bevacizumab. The report does not say which treatment helped or caused side effects. Treatment decisions should be made with a doctor.
Does this mean pancreatic cancer always spreads to the brain?
No. This is one case report, so it cannot show how often this happens. It suggests that some patients who live longer with pancreatic cancer may develop spread to the brain or spinal cord. More research is needed. Talk with your doctor if you have new neurological symptoms.
More on Pancreatic Ductal Adenocarcinoma
View Original Abstract ↓
Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management
Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms
Related in Rheumatology
From Other Specialties
